Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874887 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
A Phase 4 study of Anti-biotic Resistance, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT00874887 is a Phase 4 study of Anti-biotic Resistance that has completed, run by Allergan. The registered enrollment target is 66 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00874887, a Phase 4 study of Anti-biotic Resistance, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
Conditions Studied
Interventions
- DRUG moxifloxacin 0.5% HCI ophthalmic solution
- DRUG gatifloxacin ophthalmic solution 0.3%
Study Locations (2)
Minnesota
- - Minneapolis
Saskatchewan
- - Saskatoon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874887
The ClinicalTrials.gov registry entry for NCT00874887 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anti-biotic Resistance appearing as the primary indexed condition, and to 2 interventions - of which moxifloxacin 0.5% HCI ophthalmic solution is the first listed.
NCT00874887 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Saskatchewan.
Frequently Asked Questions
What is clinical trial NCT00874887 about?
NCT00874887 is a clinical study titled "A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms". The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
What is the current status of trial NCT00874887?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2009-03. Estimated completion is 2009-10.
What conditions does trial NCT00874887 study?
This clinical trial studies the following conditions: Anti-biotic Resistance.
What interventions are being tested in trial NCT00874887?
The interventions under investigation include: moxifloxacin 0.5% HCI ophthalmic solution (DRUG), gatifloxacin ophthalmic solution 0.3% (DRUG).
Who is sponsoring clinical trial NCT00874887?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874887 being conducted?
This trial has 2 study locations across Minnesota, Saskatchewan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.